MatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-resistant S. pseudintermedius
21. Oktober 2021 07:00 ET
|
MatriSys Bioscience
LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the publication of research on...
MatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology Summit
29. Juli 2021 07:00 ET
|
MatriSys Bioscience
LA JOLLA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company’s CEO,...
MatriSys Bioscience Names Joyce Rico as Chief Medical Officer
25. März 2021 07:00 ET
|
MatriSys Bioscience
LA JOLLA, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce Rico, MD,...
MatriSys Bioscience Expands Licensing Agreement with UCSD School of Medicine to Develop Acne Treatment
18. März 2021 07:00 ET
|
MatriSys Bioscience
LA JOLLA, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company has licensed...
MatriSys Bioscience Raises more than $3 million to Advance its Portfolio of Products to Treat Inflammatory Skin Diseases
11. März 2021 07:00 ET
|
MatriSys Bioscience
LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that it has raised more than...
MatriSys Announces Positive Results From a Phase I Study of MSB-0221 for the Topical Treatment of Atopic Dermatitis
22. Februar 2021 14:07 ET
|
MatriSys Bioscience
- Study Reveals the Potential of Beneficial Bacteria to Treat Chronic Skin Diseases - LA JOLLA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial...
MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company
28. Mai 2020 14:11 ET
|
MatriSys Bioscience
SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by...
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors
26. Mai 2020 12:25 ET
|
MatriSys Bioscience
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors
19. Mai 2020 03:09 ET
|
MatriSys Bioscience
SAN DIEGO, May 19, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
20. März 2019 19:55 ET
|
MatriSys Bioscience
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...